{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:33:24Z","timestamp":1792978404162,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12282-026-01908-6","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:04:26Z","timestamp":1788350666000},"page":"1312-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor\u2013positive, HER2-negative metastatic breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-9115","authenticated-orcid":false,"given":"Yosuke","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-648X","authenticated-orcid":false,"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7328-6729","authenticated-orcid":false,"given":"Masahiro","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-1926","authenticated-orcid":false,"given":"Jun","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-9426","authenticated-orcid":false,"given":"Meiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9290-6816","authenticated-orcid":false,"given":"Lina","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hosonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-3708","authenticated-orcid":false,"given":"Ippei","family":"Fukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuyo","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-1090","authenticated-orcid":false,"given":"Nami","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-3247","authenticated-orcid":false,"given":"Takayuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-9377","authenticated-orcid":false,"given":"Takayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1908_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1908_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407086.","journal-title":"N Engl J Med"},{"key":"1908_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, Phase 3 trial. Lancet. 2023;402:1423\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-X.","journal-title":"Lancet"},{"key":"1908_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol. 2025;43:285\u201396. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"J Clin Oncol"},{"key":"1908_CR5","doi-asserted-by":"publisher","first-page":"e2400898","DOI":"10.1200\/PO-24-00898","volume":"9","author":"N Mai","year":"2025","unstructured":"Mai N, Klar Lieberman MMK, Ferraro E, Bromberg M, Chen Y, Razavi P, et al. Sequential antibody-drug conjugate therapy in patients with metastatic breast cancer treated with sacituzumab govitecan and trastuzumab deruxtecan. JCO Precis Oncol. 2025;9:e2400898. https:\/\/doi.org\/10.1200\/PO-24-00898.","journal-title":"JCO Precis Oncol"},{"key":"1908_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","volume":"131","author":"F Poumeaud","year":"2024","unstructured":"Poumeaud F, Morisseau M, Cabel L, Gon\u00e7alves A, Rivier C, Tr\u00e9dan O, et al. Efficacy of administration sequence: Sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer. Br J Cancer. 2024;131:702\u20138. https:\/\/doi.org\/10.1038\/s41416-024-02766-9.","journal-title":"Br J Cancer"},{"key":"1908_CR7","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-24-3435","volume":"31","author":"S Kimbung","year":"2025","unstructured":"Kimbung S, Veerla S, Muhammad K, Ehinger A, Vallon-Christersson J, Malmberg M, et al. Global transcriptional complexity of estrogen receptor-low positive breast cancers in the prospective Swedish population-based SCAN-B cohort. Clin Cancer Res. 2025;31:2695\u2013709. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3435.","journal-title":"Clin Cancer Res"},{"key":"1908_CR8","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023;41:3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864.","journal-title":"J Clin Oncol"},{"key":"1908_CR9","unstructured":"Clinicaltrials.Gov. Trade DXd. Trastuzumab deruxtecan and datopotamab deruxtecan in HER2-negative metastatic breast cancer. ClinicalTrials.gov identifier: NCT06533826. https:\/\/clinicaltrials.gov\/study\/NCT06533826 Accessed 31 May 2026"},{"key":"1908_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2023;43:297\u2013337. https:\/\/doi.org\/10.1002\/cac2.12387.","journal-title":"Cancer Commun (Lond)"},{"key":"1908_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","volume":"16","author":"W Chen","year":"2026","unstructured":"Chen W, Gupta A, Mai N, Nag S, Lau JS, Singh S, et al. Trastuzumab deruxtecan resistance via loss of HER2 expression and binding. Cancer Discov. 2026;16:235\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0647.","journal-title":"Cancer Discov"},{"key":"1908_CR12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","volume":"31","author":"RO Abelman","year":"2025","unstructured":"Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, et al. TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer. Clin Cancer Res. 2025;31:1966\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2771.","journal-title":"Clin Cancer Res"},{"key":"1908_CR13","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/jnci\/djaf220","volume":"117","author":"P Tarantino","year":"2025","unstructured":"Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, O\u2019Meara T, et al. Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. J Natl Cancer Inst. 2025;117:2327\u201335. https:\/\/doi.org\/10.1093\/jnci\/djaf220.","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01908-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01908-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01908-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:03:32Z","timestamp":1792976612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01908-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1908"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01908-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yosuke Aoyama has received honoraria for lectures from Taiho, MSD, Pfizer, Eli Lilly, Daiichi Sankyo, Eisai, Kyowa Kirin, Chugai Pharmaceutical, and Gilead Sciences. Yukinori Ozaki has received honoraria from Eli Lilly, Pfizer, Daiichi Sankyo, AstraZeneca, Chugai, and Kyowa Kirin. Jun Masuda received honoraria from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, and Nippon Kayaku and consulting\/advisory fees from Eli Lilly and SB-TEMPUS. Meiko Nishimura has received honoraria from MSD, Daiichi Sankyo, Pfizer, Eisai, Kyowa Kirin, Chugai Pharmaceutical, and Eli Lilly Japan K.K. Toshimi Takano received honoraria from Daiichi-Sankyo, Eli Lilly, Gilead Sciences, and MSD. Takayuki Ueno received honoraria for lectures from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Guardant Health Japan Corp., Daiichi Sankyo Co., Ltd., and Exact Sciences Co., and a grant from Eli Lilly Japan K.K. and Gilead Sciences, Inc.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Board of Cancer Institute Hospital, Japanese Foundation for Cancer Research (approval number 2023-GB-051). All procedures were performed in accordance with the ethical standards of the Institutional Research Committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because of the retrospective nature of the study, patients from whom written informed consent could not be obtained were informed about the study and given the opportunity to opt out.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No identifiable individual data are included in this manuscript.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}